Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

Biotechnology • Healthcare • Mountain View, CA, United States • ANRO (NYQ)

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

650 200 0412 650 Castro Street, Mountain View, CA 94041, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Chardan Capital Raises Alto Neuroscience (NYSE:ANRO) Price Target to $30.00 - MarketBeat
MarketBeat • Jan 5
Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating - Investing.com India
Investing.com India • Jan 5
Alto Neuroscience Stock Rockets 51% With 8-Day Winning Streak - Trefis
Trefis • Dec 20
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company - Yahoo Finance
Yahoo Finance • Dec 26
Alto Neuroscience, Inc.'s (NYSE:ANRO) Institutional Investors Lost 10% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
富途牛牛 • Jan 1

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Alto Neuroscience, Inc. had layoffs?
No layoff events have been recorded for Alto Neuroscience, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has approximately 76 employees.
What industry is Alto Neuroscience, Inc. in?
Alto Neuroscience, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Alto Neuroscience, Inc. a publicly traded company?
Yes, Alto Neuroscience, Inc. is publicly traded under the ticker symbol ANRO on the NYQ. The company has a market capitalization of approximately $0.57 billion.
Where is Alto Neuroscience, Inc. headquartered?
Alto Neuroscience, Inc. is headquartered in Mountain View, CA, United States at 650 Castro Street, Mountain View, CA 94041, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.